Hepatitis B virus (HBV) causes either acute or chronic liver diseases. Chronic hepatitis B (CHB) often progresses to the development of cirrhosis and hepatocellular carcinoma. As HBV is extremely noncytopathic, immunological events play a key role in the infection outcome. Indeed, adaptive immune responses trigger viral clearance during acute infection and viral persistence reflects the failure to generate and maintain such responses. Current therapies for patients with CHB rely on direct-acting antivirals (DAAs) that suppress viral replication without eradicating HBV from the liver. Cure of CHB may well require combining these and forthcoming DAAs with immune-stimulating approaches of different nature and function. Here, we review the relative potential of these combination therapies.

Iannacone, M., Andreata, F., Guidotti, L. (2022). Immunological insights in the treatment of chronic hepatitis B. CURRENT OPINION IN IMMUNOLOGY, 77(August 2022) [10.1016/j.coi.2022.102207].

Immunological insights in the treatment of chronic hepatitis B

Andreata, Francesco;
2022

Abstract

Hepatitis B virus (HBV) causes either acute or chronic liver diseases. Chronic hepatitis B (CHB) often progresses to the development of cirrhosis and hepatocellular carcinoma. As HBV is extremely noncytopathic, immunological events play a key role in the infection outcome. Indeed, adaptive immune responses trigger viral clearance during acute infection and viral persistence reflects the failure to generate and maintain such responses. Current therapies for patients with CHB rely on direct-acting antivirals (DAAs) that suppress viral replication without eradicating HBV from the liver. Cure of CHB may well require combining these and forthcoming DAAs with immune-stimulating approaches of different nature and function. Here, we review the relative potential of these combination therapies.
Articolo in rivista - Review Essay
Antiviral Agents; Hepatitis B virus; Humans; Hepatitis B; Hepatitis B; Chronic; Hepatitis C; Chronic; Liver Neoplasms;
English
16-mag-2022
2022
77
August 2022
102207
none
Iannacone, M., Andreata, F., Guidotti, L. (2022). Immunological insights in the treatment of chronic hepatitis B. CURRENT OPINION IN IMMUNOLOGY, 77(August 2022) [10.1016/j.coi.2022.102207].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/417580
Citazioni
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
Social impact